| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
New York University School of Medicine and New York Harbor Healthcare System (J.R., F.F., P.L.S., Z.P., A.Z.O., G.I.P.-P., C.-H.T., M.J.B.), New York, New York 10010; and University of California San Francisco School of Medicine (M.S.M.), San Francisco, California 94143
Address all correspondence and reprint requests to: Martin J. Blaser, M.D., New York University School of Medicine, 550 First Avenue, OBV A-606, New York, New York 10016. E-mail: Martin.Blaser{at}med.nyu.edu.
| Abstract |
|---|
|
|
|---|
Objective: We sought to determine whether the presence of Helicobacter pylori affects gastric and systemic levels of leptin and ghrelin.
Design, Setting, and Patients: We consecutively enrolled 256 patients referred for upper endoscopy at a Veterans Affairs outpatient endoscopy center.
Outcomes: We obtained fasting serum, fundic and antral biopsies, and gastric juice. Based on histological, biochemical, and serological assays, patients were categorized as H. pylori+ or H. pylori–. Leptin and total ghrelin levels in serum, gastric biopsies, and gastric juice were determined by specific ELISAs.
Results: Of the 256 subjects, 120 were H. pylori+ and 96 were H. pylori–; 40 patients of indeterminate status were excluded. Serum and fundic leptin levels correlated with body mass index in the H. pylori+ (r = 0.35; P < 0.0001 and r = 0.35; P < 0.0001, respectively) and H. pylori– (r = 0.65; P < 0.0001 and r = 0.41; P < 0.0001, respectively) groups, but H. pylori+ subjects had significantly lower serum leptin levels [median 2.2 ng/ml (interquartile range 0.9–4.6) vs. 4.0 ng/ml (1.7–7.2); P = 0.0003]. Serum ghrelin levels were similar in the H. pylori+ and H. pylori– groups [median 1651 pg/ml (interquartile range 845-2247) vs. 1629 pg/ml (992–2886); P = 0.23]. H. pylori status did not significantly affect gastric biopsy leptin and ghrelin levels. Ghrelin levels in gastric juice varied over 4 log10 (<80–776,000 pg/ml) and correlated with gastric juice pH in the H. pylori+ group (r = 0.68; P < 0.0001).
Conclusions: These findings provide evidence that H. pylori status affects leptin and ghrelin homeostasis, presumably via intragastric interactions.
| Introduction |
|---|
|
|
|---|
Ghrelin is a peptide hormone predominantly produced by the X/A cells in the gastric oxyntic mucosa (5). Ghrelin stimulates food intake, decreases energy expenditure, and promotes weight gain (6). In contrast to leptin, serum ghrelin levels are inversely related to adipose tissue mass and may help maintain energy homeostasis when nutrients are scarce (7). Ghrelin also exerts anti-ulcerative effects in the rat stomach, perhaps via the ghrelin type 1b receptor, which has been identified in the human stomach and esophagus (8, 9). However, whether ghrelin acts locally in the gastrointestinal lumen via gastric secretions has not been examined.
Helicobacter pylori, a persistent colonizer of the human stomach, is associated with acute gastritis (neutrophil predominance), peptic ulcer disease, and gastric adenocarcinoma. The H. pylori-induced inflammatory response affects many gastric cell types, including those responsible for leptin and ghrelin production (10). Elimination of H. pylori after antimicrobial therapy has been reported to increase nutrition and weight, suggesting that H. pylori could play a role in the regulation of leptin and ghrelin expression (11, 12). In previous studies, H. pylori colonization has been associated with high, equivalent, or low circulating leptin levels (11, 13, 14, 15, 16); the relationship between H. pylori status and ghrelin levels is also uncertain (14, 15, 16, 17, 18, 19, 20, 21, 22).
We previously found that eradication of H. pylori in adult males resulted in a significant (2.4%) increase in body mass index (BMI), with a concomitant 25% increase in integrated (mean of fasting and post-meal) leptin levels and a 76% increase in integrated ghrelin levels (41). Therefore, we hypothesized that gastric H. pylori colonization reduces circulating levels of leptin and ghrelin, perhaps by inhibiting their gastric production. We also hypothesized that ghrelin and leptin are present in gastric secretions and that H. pylori colonization may affect their levels in gastric juice. To test these hypotheses, we examined gastric, circulating, and gastric juice levels of leptin and ghrelin in well-defined fasting H. pylori+ and H. pylori– adult male subjects.
| Patients and Methods |
|---|
|
|
|---|
At the ambulatory endoscopy unit at the Manhattan campus of the Veterans Affairs New York Harbor Healthcare System, we prospectively recruited male adults of at least 18 yr of age referred for routine upper endoscopy for any indication. To exclude gender as a variable, because females have higher average leptin levels, only male patients were studied (23). Participants also were excluded if they had known coagulopathy, history of esophageal or gastric varices, previous gastric surgery, or treatment with antibiotics, steroids, or immunomodulating agents in the month before enrollment. The Institutional Review Board of New York University School of Medicine approved the study protocol, and written informed consent was obtained from all participants.
Clinical evaluation and specimen collection
All patients presented after a 12-h overnight fast. Before the scheduled endoscopy, a physician conducted a preprocedure evaluation, including history and physical examination. Demographic and clinical information was collected via questionnaire administered by trained interviewers at study entry. Participants self-reported ethnic designation as White non-Hispanic, Black non-Hispanic, Hispanic, or Asian. Height and weight was recorded for each participant and BMI calculated as weight (kilograms) divided by height (meters squared). Just before endoscopy, 15 ml blood was collected, centrifuged, and stored as serum at –20 C until examined.
Endoscopy
A complete endoscopic evaluation of the esophagus, stomach, and duodenum up to the second portion was performed with an Olympus GIF-130 or GIF-160 videoendoscope (Olympus America, Melville, NY) after iv administration of meperidine and midazolam. Upon endoscope entry into the stomach, approximately 15 ml gastric secretion was collected for pH and peptide determination. Biopsies, which included epithelium and mucosa, were obtained from the gastric antrum for rapid urease testing (Hpfast; GI Supply, Camp Hill, PA) and from the gastric antrum, fundus, and body for culture, histological examination, and biochemical testing. Two biopsies from each site were studied. The physicians performing endoscopy were blinded to the H. pylori status of the subjects and used identical technique in obtaining biopsies from each subject. Biopsy samples measuring 8 mm3 were rinsed in phosphate buffered saline (pH 7.4) and homogenized. Gastric biopsies were stored at –80 C and gastric juice samples at –20 C.
Determination of H. pylori status
Serum was evaluated for IgG antibodies against H. pylori whole-cell and cagA antigens by ELISA, with results expressed as OD ratios relative to laboratory standards, as previously described (24, 25). Values were considered positive if the OD ratio was 1.0 or higher for the whole-cell antigen assay and 0.35 or higher for the cagA antigen assay. Patients were categorized as H. pylori+ if H. pylori was isolated on culture of the gastric biopsy or if positive in at least two of the following tests: rapid urease assay, histological examination of gastric biopsy specimens for bacterial cells with characteristic morphology, or assay for serum IgG antibodies to H. pylori group or cagA antigens. Patients of indeterminate H. pylori status were positive in only one of these four tests.
Pathology
Body and antral biopsies were examined by specialized gastrointestinal pathologists. Each sample was evaluated for the presence and grade of chronic gastritis, acute gastritis, and atrophy/intestinal metaplasia in the body and antrum, according to the updated Sydney System: 0 (none), 1 (mild), 2 (moderate), or 3 (marked) (26).
Tissue and serum peptide determination
An ELISA (R&D systems, Minneapolis MN) was used to measure leptin in biopsy homogenates, serum, and gastric juice samples. Concentrations in biopsies were normalized based on biopsy protein (picograms per milligram protein) (BCA Protein Assay; Pierce Biotechnology, Rockford IL), and in serum or gastric juice per milliliter. As described by the manufacturer, the intraassay and interassay variabilities are 3.2 and 4.1%, respectively, and the minimum detectable leptin level is 0.0078 ng/ml. A competitive enzyme immunoassay (Phoenix Peptide, Burlingame CA) was used to measure ghrelin in the biopsy homogenates, serum, and gastric juice samples. The assay uses an antibody directed against the C-terminal fragment of the ghrelin peptide and detects acyl, des-acyl, and other minor forms of ghrelin. The intraassay and interassay variability of the assay are 5 and 14%, respectively, and the minimum detectable ghrelin level is 80 pg/ml. All tests were performed at least in duplicate. Identical control samples were examined for each immunoassay plate; if values for the controls were outside the interassay variability reported by the manufacturer, all samples in the plate were reassayed.
Statistical analysis
Data are expressed as mean ± SD or median and interquartile range (IQR) (25–75th percentile), depending on the distribution of the values. Continuous variables were compared using Students t test on log-transformed data after controlling for possible confounders [age, smoking status, gastric pH, BMI, and alcohol, proton pump inhibitor (PPI), histamine 2 (H2) blocker, or nonsteroidal antiinflammatory drug (NSAID) use] in a multivariate linear regression. We defined the thresholds for significance to maximize statistical rigor. For the t test analyses, we used the Bonferroni adjustment to establish a conservative threshold of P
0.005 for significance by dividing 0.05 by 10, the number of comparisons performed. Correlations were analyzed using the Spearman rank test, with a value of P
0.001 considered as significant to allow for 5% overall type I error. Categorical variables were compared using the
2 test, with a significance threshold of P
0.008 (0.05 divided by 6, the number of comparisons performed). Statistical analysis was performed using SPSS software version 13.0 for Windows (SPSS Inc., Chicago, IL).
| Results |
|---|
|
|
|---|
Among the 256 patients consecutively enrolled, 96 were H. pylori–, and 120 were H. pylori+; 40 patients of indeterminate status were excluded from further analysis. The most common indications for endoscopy in the H. pylori+ and H. pylori– groups were iron-deficiency anemia (n = 52), heme-positive stool (n = 44), gastroesophageal reflux disease (GERD) (n = 32), dyspepsia (n = 26), Barretts esophagus follow-up (n = 25), and dysphagia (n = 14) and did not significantly vary according to H. pylori status. The H. pylori+ and H. pylori– groups did not differ significantly in age, BMI, or aspirin, alcohol, or NSAID use; however, as expected, Black and Hispanic persons were overrepresented in the H. pylori+ group (27). Although smoking was more prevalent in the H. pylori+ group than in the H. pylori– group, this difference was not statistically significant. Compared with H. pylori– subjects, H. pylori+ subjects used antisecretory (PPI or H2 blocker) medications at lower rates, although this difference (P = 0.03) did not meet our standard for significance (P < 0.008). As expected, H. pylori+ subjects had higher gastric juice pH (10), a phenomenon observed only in antisecretory medication nonusers (Table 1
).
|
|
As expected, serum leptin levels were correlated with BMI in all subjects (r = 0.51; P < 0.0001), and in the H. pylori+ and H. pylori– subsets (r = 0.35; P < 0.0001 and r = 0.65; P < 0.0001, respectively) (Figure 1
). Adjusted circulating leptin levels were significantly lower in H. pylori+ than H. pylori– subjects [median 2.2 ng/ml (IQR 0.90–4.6) vs. 4.0 ng/ml (1.7–7.2); P = 0.0003] (Table 3
) but among the H. pylori+ subjects did not significantly vary by cagA status (supplemental Table 1, published as supplemental data on The Endocrine Societys Journals Online web site at http://jcem.endojournals.org). Reflecting the slope differences in Fig. 1
, the serum leptin/BMI ratio was somewhat lower in the H. pylori+ group than in the H. pylori– group [median 0.08 ng·m2/ml·kg (IQR 0.04–0.16) vs. 0.13 pg-m2/ml-kg (0.06–0.26); P = 0.008] in a multivariate analysis (Table 3
).
|
|
We were unable to detect the presence of leptin in gastric juice samples from any of 10 subjects with known high gastric and circulating leptin levels; gastric pH ranged from 2–8. In addition, leptin added to gastric juice samples with pH values ranging from 2–8 could not be detected, and measured levels of exogenously added leptin progressively increased as gastric juice samples were sequentially diluted (data not shown).
Serum, gastric, and gastric juice ghrelin
Circulating ghrelin levels obtained from the fasting subjects varied over a relatively small range (2- to 3-fold) and were similar in the H. pylori+ and H. pylori– groups [median 1651 pg/ml (IQR 845-2247) vs. 1629 pg/ml (992-2886); P = 0.23]; gastric tissue ghrelin levels also did not significantly differ according to H. pylori status. In contrast, gastric juice ghrelin levels varied over four orders of magnitude (<80 to 776,000 pg/ml). Values were somewhat higher in H. pylori+ than in H. pylori– subjects [median 1101 pg/ml (IQR 390–23413) vs. 711 pg/ml (323-1851); P = 0.02] (Table 3
). Log10 ghrelin levels in gastric juice correlated with pH in the H. pylori+ group (r = 0.68; P < 0.0001), regardless of PPI use, and in the H. pylori– group for PPI users (r = 0.51; P = 0.001) but not for PPI nonusers (Fig. 2
). The relationship was present in persons with cagA+ (both PPI users and nonusers) and cagA– (only PPI users) H. pylori strains (supplemental Figs. 2 and 3, published as supplemental data on The Endocrine Societys Journals Online web site at http://jcem.endojournals.org).
|
In the fundus, leptin and ghrelin levels correlated in the H. pylori+ group (r = 0.34; P < 0.0001) but not significantly in the H. pylori– group (r = 0.20; P = 0.07).
| Discussion |
|---|
|
|
|---|
One explanation for our findings is that H. pylori colonization inhibits gastric leptin production, perhaps by inducing atrophic changes in leptin-producing tissues, consistent with our finding of a greater degree of antral atrophy/intestinal metaplasia in H. pylori+ compared with H. pylori– subjects. The presence of H. pylori may also modulate gastric cytokine function, thereby reducing circulating levels. Because we did not find an effect of H. pylori status on gastric leptin levels, another possibility is that H. pylori colonization, instead of affecting leptin production, alters the balance of leptin release into the luminal and systemic compartments. These hypotheses should be examined in future studies. Alternatively, H. pylori+ persons may have less adiposity relative to BMI and therefore lower serum leptin levels compared with H. pylori– persons. A recent study of indigenous Amerindians provided evidence that H. pylori+ subjects had more athletic body morphometry, consistent with this hypothesis (29).
We found that H. pylori status did not affect antral, fundic, or circulating ghrelin levels, contrary to our hypothesis and to previous reports that found lower (14, 15, 19, 20) circulating ghrelin levels in H. pylori+ compared with H. pylori– individuals; three other previous studies also found no significant difference according to H. pylori status (16, 18, 21). One explanation for our findings is that the effect of long-term carriage of H. pylori on ghrelin production is minimal due to host adaptation; in contrast, eradication of H. pylori may acutely induce production of ghrelin (12). Another possibility is that any effect of H. pylori on gastric hormone production may be obscured by confounding variables that are minimized when patients serve as their own controls in eradication studies.
The levels of circulating leptin and ghrelin in the blood reflect their usually reciprocal roles in body weight regulation (7, 28), but the relationship between gastric production of the two hormones in the stomach has not been studied. The positive correlation we observed between fundic leptin and ghrelin levels in H. pylori+ persons suggests that H. pylori may be involved in the coordinate regulation of gastric leptin and ghrelin production; conversely, lack of correlation in H. pylori– subjects suggest an absence of such coordination.
Despite a growing body of literature demonstrating that ghrelin regulates local gastrointestinal function, we are not aware of previous studies examining for the presence of ghrelin in gastric juice. We found that ghrelin is present in gastric juice and that levels vary over a large (4 log10) range, much greater than that for either gastric or serum ghrelin. We performed experiments demonstrating that exogenous ghrelin is stable after incubation with gastric juice samples with pH ranging from 2–8 and that endogenous ghrelin levels in gastric juice samples are consistently measured by immunoassay over a range of dilutions (data not shown). In contrast, we were unable to detect leptin in gastric juice, although other investigators have reported detecting gastric juice leptin using RIA (30).
Long-term H. pylori carriage results in progressive gastric atrophy with loss of acid-producing parietal cells (10), and our observation in these older men that gastric juice pH was higher in H. pylori+ than in H. pylori– subjects is consistent with this trend. Previous literature shows that exogenous administration of ghrelin may stimulate (31), inhibit (32), or have no effect (33) on gastric acid secretion, possibly depending on route of administration. Our finding that gastric juice ghrelin levels were related to gastric juice pH, regardless of PPI use (Figure 2
), suggests that gastric juice ghrelin inhibits gastric acid secretion or, alternatively, that gastric acidity inhibits release of ghrelin into gastric juice. Another hypothesis is that H. pylori, by decreasing gastric acidity, stimulates ghrelin secretion into the gastric lumen. If this newly discovered relationship is confirmed, new mechanisms of gastric acid regulation involving ghrelin should be explored.
In this study, we chose to assess total ghrelin levels in fasted patients. Although ghrelin levels vary throughout the day according to caloric intake, Cummings et al. (34) found that prebreakfast fasting ghrelin levels strongly correlated with 24-h integrated area under the curve ghrelin values (r = 0.87; P < 0.0004). Thus, almost all studies of ghrelin physiology have relied on a single determination of fasting ghrelin as a surrogate for overall ghrelin levels. Ghrelin circulates in acyl, des-acyl, and other minor forms. We measured total ghrelin levels for the following reasons. 1) Most studies on ghrelin physiology have assessed total, not acyl, ghrelin. 2) Measurement of total ghrelin levels reflects the complex functions of the various ghrelin isoforms, including acyl and des-acyl ghrelin. 3) Accurate measurement of acyl-ghrelin in serum requires acidification of samples at the time of collection to pH 4, which we plan to do in future studies to add this dimension to the analyses (35). Similarly, we measured fasting morning leptin levels as a surrogate marker for 24-h leptin levels, because fasting morning leptin levels strongly correlate with BMI (28) and in accordance with numerous publications examining other aspects of human physiology (36).
In the present study, we describe associations between H. pylori colonization and leptin and ghrelin levels in stomach, circulation, and gastric juice, but our study design does not permit examining the mechanisms for these findings. Our study is limited because all of our subjects were men, not permitting conclusions about women. Because the majority of the patients we studied were overweight, although we controlled for potential confounders, it is possible that unanticipated variables, including other medications or medical conditions, may have influenced our results. Variation among H. pylori strains also may contribute to the differences in study results.
Our study population consisted of largely overweight, older American men of diverse ethnicities, whereas several previous studies have examined Japanese patients, mostly with BMI less than 30 (17, 19, 20, 22). However, we believe that our obese subjects are representative of the generally obese older U.S. male population; mean BMI in our study was 27, whereas in 2002, American males had a mean BMI of 28 (37). The prevalence of H. pylori in our cohort was 47%, similar to a seroprevalence of 32.5% in a sample of the general U.S. adult population and 56.9% in those over age 70 (27). Although Hispanic and Black subjects were overrepresented in the H. pylori+ group, adjustment for ethnicity did not affect our analyses. These findings are consistent with two recent studies demonstrating no relationship between ethnicity and serum leptin levels (38, 39).
Strengths of our study include our ability to control for confounding variables, particularly BMI, age, alcohol, PPI or NSAID use, smoking status, and gastric pH. We also used five validated tests to determine H. pylori status (40) and removed patients of indeterminate status to maximize case ascertainment; most previous studies have used much more limited criteria to assess H. pylori status (13, 14, 15, 16, 17, 18, 19, 20, 21, 22).
In conclusion, H. pylori colonization was associated with reduced circulating leptin levels, independent of BMI, and fundic ghrelin and leptin levels were directly related. Ghrelin is present in gastric juice over a large range of concentrations and is strongly correlated with gastric pH. Our findings are consistent with the hypothesis that H. pylori, a persistent resident of the human stomach, may have an impact on human health and disease by its involvement in the regulation of leptin and ghrelin expression.
| Footnotes |
|---|
Disclosure Statement: The authors have nothing to disclose.
First Published Online April 8, 2008
Abbreviations: BMI, Body mass index; H2, histamine 2; IQR, interquartile range; NSAID, nonsteroidal antiinflammatory drug; PPI, proton pump inhibitor.
Received September 13, 2007.
Accepted March 27, 2008.
| References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |